v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating Expenses        
Research and development expenses $ 1,722,364 $ 532,587 $ 4,806,845 $ 1,461,416
Acquisition of in-process research and development 50,953 2,000,000 566,583 2,000,000
General and administrative expenses 1,338,113 422,958 3,391,105 1,282,239
Operating Loss (3,111,430) (2,955,545) (8,764,533) (4,743,655)
Other Income (Expense)        
Forgiveness of PPP loan and related accrued interest 163,771
Interest expense (186,209) (362) (222,660)
Interest income 1,771 12 8,525 859
Net Operating Loss Before Income Tax Benefit (3,109,659) (3,141,742) (8,592,599) (4,965,456)
Income Tax Benefit 122,442 70,457 348,859 286,421
Net Loss $ (2,987,217) $ (3,071,285) $ (8,243,740) $ (4,679,035)
Net Loss per Common Share - Basic and Diluted $ (0.19) $ (0.55) $ (0.54) $ (0.84)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted 15,531,442 5,594,370 15,177,306 5,542,026

Source